caa a22 4500 477058280 CHVBK 20180405111353.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203778 doi (NATIONALLICENCE)springer-10.1007/BF00203778 Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration [Elektronische Daten] [S. Nozaki, T. Nakagawa, A. Nakata, S. Yamashita, K. Kameda-Takemura, T. Nakamura, Y. Keno, K. Tokunaga, Y. Matsuzawa] In order to determine whether there is a difference in the effect of the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin on cholesterol synthesis between the morning and the evening, we studied the 24-h profile of mevalonate in plasma and urine in 11 subjects with heterozygous familial hypercholesterolaemia. In study 1, eight subjects with familial hypercholesterolaemia took pravastatin (20 mg) once in the morning, and another 20-mg dose in the evening after a 1-week wash-out period. In study 2, five subjects with familial hypercholesterolaemia took pravastatin (20 mg per day) in the morning on 3 consecutive days and on 3 days in the evening after a 1 day wash-out. Plasma mevalonate concentrations were reduced at 9 h and 5 h after pravastatin administration in the morning and the evening, respectively. Urinary mevalonate excretion was significantly reduced at 4-8 h after pravastatin administration in the morning (51 vs 19 nmol · h−1) and at 4-16 h after pravastatin administration in the evening (56 vs 27 nmol · h−1). Daily urinary mevalonate excretion was equally and significantly reduced by pravastatin in the morning or evening. In conclusion, we found that morning and evening administration of pravastatin caused equal reductions in plasma and urinary mevalonate concentrations. Springer-Verlag, 1996 Hypercholesterolaemia nationallicence Pravastatin nationallicence Mevalonate nationallicence cholesterol synthesis nationallicence circadian rhythm nationallicence Nozaki S. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Nakagawa T. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Nakata A. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Yamashita S. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Kameda-Takemura K. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Nakamura T. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Keno Y. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Tokunaga K. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut Matsuzawa Y. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 361-364 0031-6970 49:5<361 1996 49 228 https://doi.org/10.1007/BF00203778 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203778 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nozaki S. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Nakagawa T. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Nakata A. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Yamashita S. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Kameda-Takemura K. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Nakamura T. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Keno Y. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Tokunaga K. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 700 1- Matsuzawa Y. Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, 565, Suita, Japan aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 361-364 0031-6970 49:5<361 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer